|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.56 USD | +2.27% |
|
+3.11% | +69.52% |
| Mar. 06 | Nektar Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) | RE |
| Mar. 03 | Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran | CI |
Business description: Intellia Therapeutics, Inc.
Number of employees: 377
Sales by Activity: Intellia Therapeutics, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Development of Gene Editing-Based Therapies | 33.05M | 52.12M | 36.28M | 57.88M | 67.67M |
Geographical breakdown of sales: Intellia Therapeutics, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 33.05M | 52.12M | 36.28M | 57.88M | 67.67M |
Executive Committee: Intellia Therapeutics, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
John Leonard
CEO | Chief Executive Officer | 68 | 2017-12-31 |
Edward Dulac
DFI | Director of Finance/CFO | 51 | 2024-07-21 |
Kristy Wood
CTO | Chief Tech/Sci/R&D Officer | - | - |
Birgit Schultes
CTO | Chief Tech/Sci/R&D Officer | 63 | 2025-01-12 |
David Lebwohl
CTO | Chief Tech/Sci/R&D Officer | 71 | 2020-04-29 |
Composition of the Board of Directors: Intellia Therapeutics, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
John Leonard
BRD | Director/Board Member | 68 | 2014-06-30 |
Frank Verwiel
CHM | Chairman | 63 | 2020-01-31 |
Jesse Goodman
BRD | Director/Board Member | 74 | 2018-10-30 |
Fred Cohen
BRD | Director/Board Member | 69 | 2019-01-23 |
Georgia Keresty
BRD | Director/Board Member | 64 | 2021-04-08 |
Muna Bhanji
BRD | Director/Board Member | 63 | 2022-04-27 |
William Chase
BRD | Director/Board Member | 58 | 2023-04-13 |
Brian Goff
BRD | Director/Board Member | 57 | 2024-06-12 |
Company details: Intellia Therapeutics, Inc.
Other Biotechnology & Medical Research
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.27% | +3.11% | +92.42% | -58.97% | 1.8B | |
| -1.50% | -2.16% | -5.75% | -9.86% | 47.23B | |
| -1.60% | +0.96% | +36.55% | +21.10% | 35.27B | |
| -1.87% | -0.98% | +298.18% | +499.32% | 30.76B | |
| -0.96% | +5.28% | +35.78% | +33.65% | 29.31B | |
| +1.72% | +0.95% | +25.30% | -12.54% | 29.67B | |
| -2.36% | -3.60% | +49.46% | +197.60% | 15.16B | |
| -0.13% | +0.16% | +80.23% | +175.56% | 15.09B | |
| +0.52% | +2.07% | +41.64% | +14.33% | 14.42B | |
| +0.25% | -5.68% | +3,621.17% | +3,898.31% | 13.9B | |
| Average | -0.37% | +2.69% | +427.50% | +475.85% | 23.26B | |
| Weighted average by Cap. | -0.80% | +3.03% | +279.58% | +327.44% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NTLA Stock
- Company Intellia Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
